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Abstract We aimed to analyze the value of seizure
reduction and radiological response as prognostic markers of
survival in patients with low-grade glioma (LGG) treated
with temozolomide (TMZ) chemotherapy. We retrospec-
tively reviewed adult patients with a progressive LGG and
uncontrolled epilepsy in two hospitals (VUmc Amsterdam;
MCH The Hague), who received chemotherapy with TMZ
between 2002 and 2014. End points were a C50 % seizure
reduction and MRI response 6, 12 and 18 months (mo) after
the start of TMZ, and their relation with progression-free
survival (PFS) and overall survival (OS). We identified 53
patients who met the inclusion criteria. Seizure reduction
was an independent prognostic factor for both PFS (HR 0.38;
95 % CI 0.19–0.73; p = 0.004) and OS (HR 0.39; 95 % CI
0.18–0.85; p = 0.018) after 6mo, adjusting for age and
histopathological diagnosis, as well as after 12 and 18mo.
Patients with an objective radiological response showed a
better OS (median 87.5mo; 95 % CI 62.0–112.9) than
patients without a response (median 34.4mo; 95 % CI
26.1–42.6; p = 0.046) after 12mo. However, after 6 and
18moOSwas similar in patients with and without a response
on MRI. Seizure reduction is an early and consistent
prognostic marker for survival after treatment with TMZ,
that seems to precede the radiological response. Therefore,
seizure reduction may serve as a surrogate marker for tumor
response.
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Introduction
Diffuse low-grade gliomas (LGGs) are slowly growing,
diffuse infiltrative brain tumors, including astrocytomas,
mixed oligoastrocytomas and oligodendrogliomas, that
mainly affect young adults [1, 2]. Median survival gener-
ally ranges between 2 and 20 years, depending on
histopathological subtype, age, tumor size and performance
status [3–5].
Assessing response to antitumor treatment is a major
challenge in LGG patients. Diffuse LGGs are predominantly
non-contrast enhancing diffusely infiltrative tumors, ham-
pering radiographic assessment. Complete radiological
responses are rare, and symptomatic improvement is not
always accompanied by a radiological response [6–8].
Therefore, the use of objective radiological response as an
outcome measure has serious drawbacks, and there is a
strong need for complementary measures to determine out-
come and to define the benefit of antitumor treatment [8].
Seizures often are the sole clinical symptom of a diffuse
LGG, occurring in 70–90 % of patients during the course
of the disease [9–11]. Apart from treatment with
antiepileptic drugs (AEDs), antitumor treatment itself may
contribute to a reduction in seizure frequency. Seizure
reduction has been reported both after focal fractionized
irradiation and after chemotherapy with either
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procarbazine, lomustine and vincristine (PCV) [12] or
temozolomide (TMZ) [13–16]. Furthermore, several stud-
ies showed that a reduction in seizure frequency may occur
in the absence of a radiological response on MRI after
treatment [13, 15, 17–19]. We previously showed that a
seizure reduction 6 months (mo) after the start of TMZ is
associated with a longer survival in LGG patients [20].
Possibly, seizure reduction may serve as an additional
outcome measure for tumor response after antitumor
treatment. However, its precise value in comparison with
radiological response is still unknown.
In the current study, we analyzed the value of seizure
reduction and radiological response as prognostic markers
of survival in patients with progressive LGG and uncon-
trolled epilepsy that were treated with TMZ.
Patients and methods
Study population
We studied adult (C18 years) patients with a grade II
glioma according to the World Health Organization
(WHO) criteria, treated at the Medical Center Haaglanden,
The Hague, or VU University Medical Center, Amsterdam,
between January 2002 and January 2014. Using institu-
tional databases, we selected patients who met the fol-
lowing inclusion criteria: (1) histopathological diagnosis of
a supratentorial WHO grade II astrocytoma, oligoastrocy-
toma or oligodendroglioma; (2) radiological and/or clinical
signs of tumor progression; (3) treatment with TMZ for at
least 6 cycles, or until renewed tumor progression or
unacceptable toxicity emerged; (4) presence of uncon-
trolled epilepsy, defined as at least 1 seizure 3mo before the
start of TMZ, despite use of AEDs and not attributable to
subtherapeutic AED serum levels; (5) no other antitumor
therapy during TMZ treatment; (6) availability of follow-
up data on seizure outcome after 6, 12 or 18mo and on
survival. We excluded patients with an increased AED
dose or switch in AED regimen during TMZ treatment.
Patients
We collected additional data from the hospital medical
charts on date and type of first symptoms at diagnosis,
antitumor treatment before and after TMZ, seizure semi-
ology and frequency and steroid use. We classified seizures
as partial (simple or complex), generalized, or a combi-
nation of both. We divided seizure frequency into two
categories, based on the median score: C1 seizure/week
or\1/week. Regarding the different types of surgery, we
made a distinction between gross-total resection, partial
resection and a biopsy. Gross-total resection was defined as
the absence of residual tumor during surgery and on
postoperative T2-weighted MRI. In case of any residual
tumor, resections were classified as partial. The local ethics
committee approved the study protocol.
Study end points
We evaluated the presence of a C50 % seizure reduction 6,
12 or 18mo after the start of TMZ treatment. A C50 %
seizure reduction was defined as a reduction of C50 % in
the number of seizures per unit of time compared to
baseline. All other seizure outcomes (a\50 % reduction in
the number of seizures, a similar or an increased seizure
frequency) were considered a\50 % seizure reduction.
Seizure reduction was based on seizure frequencies
reported by the patient, without electroencephalographic
confirmation.
We analyzed progression-free survival (PFS), defined as
duration of survival from the start of TMZ to clinical or
radiological progression, and overall survival (OS), defined
as duration of survival from the start of TMZ until death,
using the response assessment in neuro-oncology (RANO)
criteria [8].
To analyze the radiological response, two investigators
(JAFK and LD) independently measured tumor response
on MRI. In line with the RANO criteria for LGG, we
defined complete response (CR) as a complete disap-
pearance of the lesion, partial response (PR) as a C50 %
decrease and minor response (MR) as a 25–50 %
decrease of the area of the lesion. Patients with a CR,
PR or MR (i.e. an objective response) had to be stable or
improved clinically without an increased corticosteroid
dose. Progressive disease (PD) was defined as a C25 %
increase in the area of the lesion, or the development of
new lesions, or increased or new enhancement.
Stable disease (SD) was defined as any status other than
CR, PR, MR or PD. To measure the differences in the
area of the lesion, we used the change in the product of
the perpendicular T2 tumor diameters between MR
imaging at 6, 12 and 18mo, and the imaging at baseline.
In case of disagreement, which we defined as a[10 %
difference in the product of the perpendicular diameters,
the two investigators performed a consensus measure-
ment through discussion.
Statistical analysis
We performed statistical analysis using SPSS V.21.0
software. We defined the study population using descrip-
tive statistics. Differences between patients with and
without a seizure reduction were tested with the v2 or
Fisher’s exact test for categorical data and the Student t test
for continuous data. We explored both seizure outcome and
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radiological response in relation to survival (PFS and OS),
using Kaplan–Meier estimates and log-rank tests. Multi-
variable Cox modelling was applied to determine the
association between seizure reduction and survival, taking
into account two well-known prognostic factors (age and
histopathological diagnosis). We censored patients for
survival analysis at the end of the study (July 1, 2014) who
showed no evidence of renewed tumor progression after
treatment with TMZ or who were still alive.
Results
Patient characteristics
We identified 53 patients who met all the in- and exclusion
criteria. Thirteen patients were excluded due to an increase
in AED dose or a switch in AED type. Baseline charac-
teristics are outlined in Table 1. The cohort consisted of 32
patients (60.4 %) with astrocytoma, 7 (13.2 %) with
oligoastrocytoma and 14 with oligodendroglioma (26.4 %).
Twenty-three patients (43.4 %) had simple partial sei-
zures, 7 (13.2 %) complex-partial, 14 (28.3 %) generalized
and 8 (15.1 %) had a combination of both partial and
generalized seizures. Twenty-two patients (41.5 %) repor-
ted more than one seizure a week; 31 patients (58.5 %) had
less than one seizure a week. All 53 patients received AED
treatment when TMZ treatment was initiated and 34
patients (64.2 %) were on AED polytherapy at that time.
All patients underwent surgery prior to TMZ treatment:
in 5 patients (9.4 %) a gross-total resection had been per-
formed, in 25 (47.2 %) a partial resection and in 23 patients
(43.4 %) a biopsy only. Thirty-eight patients (71.7 %) had
received focal fractionated irradiation before the start of
TMZ treatment. The median time between the end of
radiotherapy and the start of TMZ was 3.9 years (range
0.8–13.9 years). Twelve patients (22.6 %) underwent a
second resection due to tumor progression. Median time
from first symptoms to the start of TMZ was 5.8 years
(Inter Quartile Range (IQR) 5.7).
Median follow-up time from the start of TMZ was
32.1mo (IQR 34.3). At last follow-up, 47/53 patients
(88.7 %) had developed tumor recurrence with a median
PFS of 20.0mo (95 % CI:13.8–26.2), and 32/53 patients
(60.4 %) had died, showing a median OS of 39.1mo (95 %
CI:27.2–50.9). Within 6mo after initiation of TMZ, 2/53
patients had developed tumor recurrence, of which 1
patient had died. Within 12mo, a total of 12/53 patients had
developed tumor recurrence, of which 5 patients had died.
Within 18mo, a total of 16/53 patients had developed
tumor recurrence, of which 8 patients had died. Three
patients in whom seizure outcome was missing at 12 and
18mo were excluded from further analysis. As a
consequence, at 6, 12 and 18mo, 51, 38 and 34 patients
were available for the analysis of seizure outcome and
survival, respectively (Supplementary figure).
Seizure outcome
Six, 12 and 18mo after initiation of TMZ treatment, 25/51
(49.0 %), 24/38 (63.2 %) and 21/34 (61.8 %) patients
showed a C 50 % seizure reduction, respectively. Of the
34 patients without tumor progression within 18mo, 17
(50.0 %) patients had a persistent C50 % seizure reduction
at 6, 12 as well as 18mo (Supplementary Fig. 1).
Various demographic and clinical variables were com-
pared between patients with and without seizure reduction,
and are outlined in Table 2. There were no statistically
significant differences between patients with and without
a C50 % seizure reduction at 6, 12 and 18mo after the start
of TMZ. AEDs were withdrawn within 18mo after the start
of TMZ in 4 patients with a C50 % seizure reduction, and
in 2 other patients AED dose was reduced. In patients
without seizure reduction, AED dose was reduced in 1
patient within 18mo.
Seizure reduction and survival
Patients with a C50 % seizure reduction at 6mo showed a
significantly longer median PFS of 26.0mo (95 % CI
15.7–36.3) compared to a median PFS of 14.0mo (95 % CI
8.0–20.0) in patients without seizure reduction (HR 0.38;
95 % CI 0.19–0.73; p = 0.004), after adjustment for age
and histopathological diagnosis (Fig. 1; supplementary
Table 1). At 12mo after the start of TMZ, a C50 % seizure
reduction also was an independent prognostic factor for
PFS (HR 0.27; 95 %CI 0.12–0.62; p = 0.002), as well as at
18mo (HR 0.24; 95 % CI 0.10–0.59; p = 0.002).
Patients with a C50 % seizure reduction at 6mo showed
a significantly longer median OS of 87.5mo (95 % CI
35.8–139.1) compared to a median OS of 30.5mo (95 % CI
20.3–40.7) in patients without seizure reduction (HR 0.39;
95 % CI 0.18–0.85; p = 0.018), adjusting for age
and histopathological diagnosis (Fig. 1; supplementary
Table 1). At 12mo after the start of TMZ, a C50 % seizure
reduction also was an independent prognostic factor for OS
(HR 0.28; 95 % CI 0.097–0.77; p = 0.015), as well as at
18mo (HR 0.31; 95 % CI 0.10–0.96; p = 0.042).
We evaluated the use of antitumor treatment after
administration of TMZ, as it might have had an effect on
OS as well. In 29/47 patients (61.7 %) who developed
tumor recurrence after TMZ treatment, new antitumor
treatment was initiated. A partial resection was performed
in 10/29 cases, of which 7 revealed a malignant transfor-
mation to a WHO grade III tumor (3 cases) or glioblastoma
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(4 other cases). Re-challenge with TMZ was started in 12
cases, radiotherapy in 8 cases, combined radio-
chemotherapy with TMZ in 3, a combination of
chemotherapy with PCV in 5, and lomustine monotherapy
in 1 case. Twelve patients received a combination of 2 or
more treatments until the last follow-up. At 6, 12 and
18mo, there was no statistically significant difference
between patients with and without a C50 % seizure
reduction with regard to the initiation of new antitumor
treatment after TMZ.
Radiological response and its association
with seizure reduction and survival
At 6mo, 11/50 patients (22.0 %) showed an objective
response to treatment, compared to 23/37 patients (62.2 %)
at 12mo, and 21/33 patients (63.6 %) at 18mo. We found
no CRs at 6, 12 and 18mo (supplementary Table 2).
The radiological response in relation to seizure reduc-
tion is outlined in Table 3. After 6mo, 7/24 patients
(29.2 %) with a C50 % seizure reduction had an objective
response on MRI, compared to 4/26 patients (15.4 %)
without a seizure reduction (p = 0.24). After 12mo 18/23
patients (78.3 %) with a C50 % seizure reduction had an
objective response on MRI, compared to 5/14 patients
(35.7 %) without a seizure reduction (p = 0.010). After
18mo 13/21 patients (61.9 %) with a C50 % seizure
reduction had an objective response, compared to 7/12
patients (58.3 %) without a seizure reduction (p = 0.84).
Of the 24 patients with a C50 % seizure reduction at 6mo,
15 patients (62.5 %) showed an objective response on MRI
at 12mo, compared to 9/26 patients (34.6 %) without a
Table 1 Baseline
characteristics















Basal ganglia/midline 5 (9.4)
Median time from first symptoms to start of TMZ, years (IQR) (n = 52) 5.8 (5.7)
Other focal symptoms at diagnosis (n = 51) 14 (27.5)
Extent of surgery
Gross-total resection 5 (9.4)




Partial simple 23 (43.4)
Partial complex 7 (13.2)
Secondary generalized 15 (28.3)




AED polytherapy 34 (64.2)
Steroid use 27 (50.9)
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seizure reduction at 6mo (p = 0.049). Fourteen of 24
patients (58.3 %) with a C50 % seizure reduction at 6mo
showed an objective response on MRI at 18mo, compared
to 7/26 patients (26.9 %) without a seizure reduction at
6mo (p = 0.025).
We analyzed the prognostic value of an objective
response on MRI for OS (Fig. 2). At 6mo, OS was similar
in patients with (median 33.6mo; 95 % CI 2.4–64.9) and
without (median 40.5mo; 95 % CI 24.8–56.3; p = 0.640)
an objective response on MRI. At 12mo, patients with an
objective response showed a better OS (median 87.5mo;
95 % CI 62.0–112.9) than patients without an objective
response (median 34.4mo; 95 % CI 26.1–42.6; p = 0.046).
At 18mo, we found no statistical difference in OS between
patients with (median 106.1mo; 95 % CI 55.1–157.1) and
without an objective response (median 47.3; 95 % CI
26.7–67.9; p = 0.096).
Discussion
TMZ is currently the preferred chemotherapy in patients
with a progressive LGG, as it is well-tolerated and rela-
tively easy to administrate [21]. Response to TMZ treat-
ment based on radiological assessment is difficult in LGG,
as on MRI a minor response is often the best achievable
response category and measuring tumor size can be chal-
lenging [7].
In the present study, we compared seizure reduction
with the response on MRI as prognostic markers for sur-
vival in patients with a progressive LGG treated with TMZ.
Seizure reduction appeared to be a consistent marker for a
survival benefit in patients with progressive LGG up to
18mo after the start of TMZ. More importantly, after 6mo,
patient’s seizure status reflected both PFS and OS, in
contrast to radiological response. Furthermore, a C50 %
seizure reduction at 6mo was associated with the occur-
rence of an objective MRI response at both 12mo and
18mo. No less than 8/17 patients with a seizure reduction
but no MRI response at 6mo, showed a radiological
response 6mo later. So, seizure reduction not only seems to
be a favorable prognostic marker for survival at different
time points from the start of TMZ, but also seems to pre-
cede the radiological response. In other words, a C50 %
seizure reduction appears to be a relatively early sign that
the tumor is responding to treatment.
Our data suggest that absence of a radiological response
should not prevent physicians from continuing TMZ
treatment. Previous studies in LGG support our findings
that radiological responses to chemotherapy are often slow
Table 2 Differences in demographic and clinical characteristics between patients with and without seizure reduction at 6, 12 and 18 months
after the start of temozolomide
Seizure reduction at 6mo (n = 51) Seizure reduction at 12mo (n = 38) Seizure reduction at 18mo (n = 34)
\50 % C50 % p value \50 % C50 % p value \50 % C50 % p value
All patients 26 (50.9) 25 (49.1) 14 (36.8) 24 (63.2) 13 (38.2) 21 (61.8)
Mean age, y (SD) 47.5 (12.6) 46.0 (11.5) 0.65 50.7 (10.8) 45.5 (11.6) 0.18 49.2 (13.4) 45.5 (11.0) 0.39
Tumor type 0.82 0.27 0.84
Astrocytoma 15 (57.7) 15 (60.0) 8 (57.1) 12 (50.0) 7 (53.8) 11 (52.4)
Oligoastrocytoma 3 (11.5) 4 (16.0) 0 4 (16.7) 1 (7.7) 3 (14.3)
Oligodendroglioma 8 (30.8) 6 (24.0) 6 (42.9) 8 (33.3) 5 (38.5) 7 (33.3)
Other focal symptoms at
diagnosis (n = 49)
4 (16.0) 9 (37.5) 0.088 1 (7.7) 6 (26.1) 0.38 1 (3.5) 5 (25.0) 0.37
Extent of surgery 0.33 0.72 0.28
Resection 17 (65.4) 13 (52.0) 9 (64.3) 14 (58.3) 10 (76.9) 11 (52.4)
Biopsy 9 (34.6) 12 (48.0) 5 (35.7) 10 (41.7) 3 (23.1) 10 (47.6)
Radiotherapy 20 (76.9) 16 (64.0) 0.31 12 (85.7) 14 (58.3) 0.080 11 (84.6) 12 (57.1) 0.096
Seizure classification 0.12 0.94 0.64
Partial 12 (46.2) 17 (68.0) 8 (57.1) 14 (58.3) 7 (53.8) 13 (61.9)
Generalized or both
partial and generalized
14 (53.8) 8 (32.0) 6 (42.9) 10 (41.7) 6 (46.2) 8 (38.1)
Seizure frequency 0.33 0.74 0.17
[1/week 17 (65.4) 13 (52.0) 8 (57.1) 15 (62.5) 6 (46.2) 15 (71.4)
\1/week 9 (34.6) 12 (48.0) 6 (42.9) 9 (37.5) 7 (53.8) 6 (28.6)
AED polytherapy 18 (69.2) 15 (60.0) 0.49 10 (71.4) 16 (66.7) 1.00 10 (76.9) 14 (66.7) 0.70
Steroid use 13 (50.0) 12 (48.0) 0.89 6 (42.9) 9 (37.5) 0.74 7 (53.8) 6 (28.6) 0.17
J Neurooncol (2016) 126:347–354 351
123
and delayed [21]. In a series of 149 patients with LGG
treated with up-front TMZ, 77 (53 %) showed an objective
response on MRI with a median time to maximum response
of 12mo (range 3–30mo) [16]. In a study of 21 patients
treated with PCV an ongoing decrease in tumor size was
observed in 20 cases, which sometimes lasted for years
after discontinuation of treatment [22]. So the observed
radiological response rate largely depends on the timing of
the assessment. Therefore, response on MRI could under-
estimate the benefit of the treatment, particularly in the
early phase after initiation of TMZ [7]. In addition, the first
25 % decrease in the area of the lesion does not qualify for
a minor response according to the RANO criteria [8, 23].
As a consequence, there will be some patients with slowly
decreasing tumor size who are regarded as non-responders
during the first months of antitumor treatment.
Altogether, the observed radiological response is not
always related to survival in LGG patients. This is sup-
ported by our data in which the objective MRI response
was not associated with a better OS after 6 and 18mo.
Although the use of more advanced imaging techniques,
such as MRI measuring tumor volume or growth rate, may
also help to overcome current flaws in assessing radio-
logical response to treatment, a marker like seizure
reduction has the advantage of being easily recordable and
applicable in clinical practice without much effort.
Table 3 Radiological response in relation to seizure reduction
6 months (n = 50) 12 months (n = 37) 18 months (n = 33)
Seizure reduction No response Response No response Response No response Response
\50 % seizure reduction 22 4 9 5 5 8
C50 % seizure reduction 17 7 5 18 7 13
Fig. 1 Seizure reduction 6, 12 and 18mo after the start of TMZ in relation to progression-free survival (a) and overall survival (b)
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Apart from being a prognostic marker for successful
antitumor treatment, seizure reduction in itself means a
clinical benefit for the patient with an LGG, as it may
contribute to an improved quality of life and better neu-
rocognitive functioning [24–26]. A reduction in seizure
frequency after TMZ treatment has previously been
described in 44–62 % of patients [13, 14, 16, 17, 20, 27].
Seizure freedom after radiotherapy has been found in
25–75 % of patients [15, 28, 29]. The precise mechanism
of action through which antitumor treatment affects seizure
status is still unknown. A reduction in the intrinsic
epileptogenicity of the tumor, by affecting the glutamate
metabolism or induction of changes in the peritumoral
microenvironment could play a role [30, 31]. Despite the
fact that after 6mo an objective radiological response was
detected in only a minority of patients with a seizure
reduction, seizure reduction could result from a decrease in
tumor size as well, albeit a small one. After all, seizure
reduction after 6mo was strongly related to the occurrence
of a tumor response on MRI later on, after 12 and 18mo.
Our current study has several limitations. First, reports
on seizure frequency are prone to recall and reporting bias,
which is inherent to the retrospective nature of the study.
Second, because of our relatively small patient population
we were unable to perform separate analyses for each type
of radiological response. For the same reason, we were
neither able to perform analyses after more than 18mo of
follow-up, which could have further strengthened our
findings. Third, we included patients with a progressive
LGG who had previously been treated with various types
of antitumor treatment, contributing to a relatively
heterogeneous patient population. In addition, patients with
unresectable tumors were overrepresented in our popula-
tion, given the 43.4 % of patients who had undergone a
biopsy before TMZ treatment, which is higher than the
general LGG population [32]. Apart from that, patient
characteristics were representative of LGG patients [33,
34], and were equally distributed among patients with and
without a seizure reduction. Furthermore, we selected only
patients without concurrent antitumor treatment and with-
out changes in the AED regimen that could influence sei-
zure outcome, eliminating major factors that could have
affected seizure outcome.
In conclusion, this is the first study that identifies seizure
reduction in LGG patients treated with TMZ both as a
prognostic marker for survival, and as a marker which
precedes MRI tumor response. We believe that seizure
reduction is suitable as a complementary outcome measure
along with radiological response in LGG patients with
uncontrolled epilepsy. Future prospective studies should
aim at a validation of patient’s seizure status as a surrogate
marker for tumor response during antitumor treatment.
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